BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19472402)

  • 1. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience.
    Cassier PA; Walter T; Eymard B; Ardisson P; Perol M; Paillet C; Chayvialle JA; Scoazec JY; Hervieu V; Bohas CL
    Cancer; 2009 Aug; 115(15):3392-9. PubMed ID: 19472402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer].
    Shi YX; Xu RH; Jiang WQ; Zhang L; Lin TY; Li YH; Xia ZJ; Luo HY; Han B; Wang F; He YJ; Guan ZZ
    Ai Zheng; 2007 Dec; 26(12):1381-4. PubMed ID: 18076807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study.
    Afchain P; Chibaudel B; Lledo G; Selle F; Bengrine-Lefevre L; Nguyen S; Paitel JF; Mineur L; Artru P; André T; Louvet C
    Bull Cancer; 2009 May; 96(5):E18-22. PubMed ID: 19435690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
    Matsumoto S; Nishimura T; Kanai M; Mori Y; Nagayama S; Kawamura J; Nomura A; Miyamoto S; Kitano T; Ishiguro H; Yanagihara K; Teramukai S; Sakai Y; Chiba T; Fukushima M
    Chemotherapy; 2008; 54(5):395-403. PubMed ID: 18781065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
    Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
    Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens].
    Yang J; Shi Y; He X; Zhou S; Dong M; Liu P; Zhang C; Qin Y; Yang S; Gui L
    Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):137-40. PubMed ID: 24796464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
    Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
    Walter T; Bruneton D; Cassier PA; Hervieu V; Pilleul F; Scoazec JY; Chayvialle JA; Lombard-Bohas C
    Clin Colorectal Cancer; 2010 Oct; 9(4):248-54. PubMed ID: 20920998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin.
    Gonzalez MA; Biswas S; Clifton L; Corrie PG
    Br J Cancer; 2003 Aug; 89(3):455-6. PubMed ID: 12888810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.
    Walter T; Planchard D; Bouledrak K; Scoazec JY; Souquet PJ; Dussol AS; Guigay J; Hervieu V; Berdelou A; Ducreux M; Arpin D; Lombard-Bohas C; Baudin E
    Lung Cancer; 2016 Jun; 96():68-73. PubMed ID: 27133753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer.
    Bouchahda M; Adam R; Giacchetti S; Castaing D; Brezault-Bonnet C; Hauteville D; Innominato PF; Focan C; Machover D; Lévi F
    Cancer; 2009 Nov; 115(21):4990-9. PubMed ID: 19637365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.
    Zaanan A; Williet N; Hebbar M; Dabakuyo TS; Fartoux L; Mansourbakht T; Dubreuil O; Rosmorduc O; Cattan S; Bonnetain F; Boige V; Taïeb J
    J Hepatol; 2013 Jan; 58(1):81-8. PubMed ID: 22989572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
    Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
    Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma.
    Chen JS; Chao Y; Yang TS; Chou WC; Chen LT; Lee KD; Lin YC
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):151-7. PubMed ID: 19455334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.
    Dussol AS; Joly MO; Vercherat C; Forestier J; Hervieu V; Scoazec JY; Lombard-Bohas C; Walter T
    Cancer; 2015 Oct; 121(19):3428-34. PubMed ID: 26058464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer.
    Quek R; Lim WT; Foo KF; Koo WH; A-Manaf A; Toh HC
    Acta Oncol; 2007; 46(7):1032-4. PubMed ID: 17917832
    [No Abstract]   [Full Text] [Related]  

  • 19. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
    Bajetta E; Catena L; Procopio G; De Dosso S; Bichisao E; Ferrari L; Martinetti A; Platania M; Verzoni E; Formisano B; Bajetta R
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):637-42. PubMed ID: 16937105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors.
    Spada F; Antonuzzo L; Marconcini R; Radice D; Antonuzzo A; Ricci S; Di Costanzo F; Fontana A; Gelsomino F; Luppi G; Nobili E; Galdy S; Cella CA; Sonzogni A; Pisa E; Barberis M; Fazio N
    Neuroendocrinology; 2016; 103(6):806-14. PubMed ID: 26789262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.